IN8BIO, Inc.
NASDAQ:INAB
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
I
|
IN8BIO, Inc.
NASDAQ:INAB
|
US |
|
Boostheat SAS
PAR:ALBOO
|
FR |
|
Zimmer Biomet Holdings Inc
NYSE:ZBH
|
US |
|
C
|
ClearVue Technologies Ltd
ASX:CPV
|
AU |
|
Emami Realty Ltd
NSE:EMAMIREAL
|
IN |
|
Marathon Petroleum Corp
NYSE:MPC
|
US |
|
M
|
Metrofile Holdings Ltd
XBER:3MA
|
ZA |
|
United Renewable Energy Co Ltd
TWSE:3576
|
TW |
|
D
|
Delta Air Lines Inc
F:OYC
|
US |
|
Gerdau SA
BOVESPA:GGBR4
|
BR |
|
Li Ning Co Ltd
HKEX:2331
|
CN |
|
Energiekontor AG
XETRA:EKT
|
DE |
|
N
|
Norsyn Crop Technology Co Ltd
SZSE:001231
|
CN |
|
D
|
Dabaco Group
VN:DBC
|
VN |
|
C
|
Curvebeam AI Ltd
ASX:CVB
|
US |
|
F
|
First Midwest Bancorp Inc
F:FM6
|
US |
|
D
|
Digital Network SA
WSE:DIG
|
PL |
|
Inspirisys Solutions Ltd
NSE:INSPIRISYS
|
IN |
|
O
|
OTP Bank Nyrt
BET:OTP
|
HU |
|
G
|
Global Indemnity Group LLC
NYSE:GBLI
|
US |
|
Gentrack Group Ltd
NZX:GTK
|
NZ |
|
Ooh!Media Ltd
ASX:OML
|
AU |
IN8BIO, Inc.
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company is headquartered in New York City, New York and currently employs 19 full-time employees. The company went IPO on 2020-11-12. The firm is focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. The firm develops ex vivo-expanded and activated gamma-delta T cell candidates based upon its capabilities in gamma-delta T cell biology, genetic engineering and cell-type-specific manufacturing capabilities, DeltEx platform. Its lead product candidate, INB-200, is a genetically modified autologous gamma-delta T cell in Phase I clinical trial. Its INB-100, its off-the-shelf allogeneic DeltEx product candidate, was developed to demonstrate the safety of donor-derived expanded and activated gamma-delta T cells that do not undergo additional genetic modification. Its INB-400 is its allogeneic DeltEx DRI product candidate to treat solid tumor cancers, including newly diagnosed glioblastoma (GBM). Its INB-300 is a preclinical program focused on developing CAR-T-enabled DeltEx DRI product candidates.
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company is headquartered in New York City, New York and currently employs 19 full-time employees. The company went IPO on 2020-11-12. The firm is focused on the discovery, development and commercialization of gamma-delta T cell therapies for the treatment of cancer. The firm develops ex vivo-expanded and activated gamma-delta T cell candidates based upon its capabilities in gamma-delta T cell biology, genetic engineering and cell-type-specific manufacturing capabilities, DeltEx platform. Its lead product candidate, INB-200, is a genetically modified autologous gamma-delta T cell in Phase I clinical trial. Its INB-100, its off-the-shelf allogeneic DeltEx product candidate, was developed to demonstrate the safety of donor-derived expanded and activated gamma-delta T cells that do not undergo additional genetic modification. Its INB-400 is its allogeneic DeltEx DRI product candidate to treat solid tumor cancers, including newly diagnosed glioblastoma (GBM). Its INB-300 is a preclinical program focused on developing CAR-T-enabled DeltEx DRI product candidates.
